Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q1 2018 · 10-Q
Revenue$8.20M$8.20M+186.9% vs Q1 2017 Net Income-$20.74M-$20.74MN/M vs Q1 2017 EPS Diluted-$0.04-$0.04N/M vs Q1 2017 Operating Income-$28,740,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
Free Cash Flowderived-$49,183,000N/M Margins · derivedOperating margin-350.7%+427.1 pt vs Q1 2017
Net margin-253.0%+509.4 pt vs Q1 2017
ended Mar 31, 2018 · filed May 9, 2018 · 39 d after period end